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Introduction The role of tumor necrosis factor-α (TNFα) is well documented in pathogenesis of chronic 
periodontitis (CP) and type 2 diabetes (T2D). Considering short half-life of TNFα, tumor necrosis factor 
receptor-2 (TNFR2) is used as prosperous surrogate marker of TNFα activity.
Objective The aim was to detect TNFR2 serum concentration and correlate it with periodontal destruc-
tion in patients with diagnosed T2D and nondiabetics.
Methods The study included 85 patients divided into three groups: T2D + CP (group T2D, n = 34); nondia-
betics + CP (Group PD, n = 27); and healthy controls (group HC, n = 24). T2D was diagnosed according to 
WHO criteria (2013) and periodontitis was diagnosed using International Workshop for a Classification 
of Periodontal Diseases and Conditions criteria (1999). TNFR2 level was measured by enzyme-linked im-
munosorbent assay (ELISA).
Results There was no difference in TNFR2 level among the groups (Kruskal–Wallis, p = 0.482). Significant 
correlation (Pearson’s correlation coefficient) was observed between clinical attachment loss (CAL) and 
TNFR2 concentration in PD group (rp = -0.460, p = 0.016). In T2D group, correlations were observed be-
tween TNFR2 concentration and CAL (rp = 0.363, p = 0.005) and periodontal inflamed surface area (PISA) 
(rp = 0.345, p = 0.046) and periodontal epithelial surface area (PESA) (rp = 0.578, p = 0.000).
Conclusion Higher concentration of TNFR2 was associated with higher CAL, PESA, and PISA scores in T2D 
group. Contrary to that, nondiabetics with higher values of CAL exhibited lower concentration of TNFR2, 
presenting potential protective effect on periodontal destruction. These results imply that diabetes may 
alter TNFR2 secretion originated from periodontium.
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 INTRODUCTION
Plaque-associated periodontal diseases are 
chronic infectious diseases caused by mixed 
microbial flora that lead to inflammation and 
destruction of tooth attachment and ultimately 
tooth loss [1]. Although bacteria of dental bio-
film are considered to be the main etiological 
factor in periodontitis, it is a well-known fact 
that a local immune and inflammatory re-
sponse to bacteria leads to destruction of peri-
odontium [2].
Key mediator of periodontal inflammation 
is tumor necrosis factor-alpha (TNFα). TNFα 
is potent proinflammatory cytokine produced 
by many cells in response to inflammation, 
infection and injury. TNFα plays a vital role 
in host defense processes and immune sur-
veillance. However, increased levels of TNFα 
exhibit harmful effects [3]. TNFα binds two 
specific TNFRs – TNFR1 and TNFR2. TNFR1 is 
expressed in most cell types, whereas immune 
cells constitutively express low levels of TNFR2 
[4]. Both receptors exist in two forms – trans-
membrane and soluble (s). The soluble forms 
compete with TNFα for TNF binding sites on 
transmembrane receptors [3]. Therefore, re-
ceptors participate in signal transduction, and 
regulate TNFα bioavailability [5].
Beneficial and pathological signals diverge 
at receptor levels. Transmembrane TNFα and 
TNFR2 are responsible mostly for prosurvival 
signals, while sTNFα and TNFR1 mediate det-
rimental effect [6]. Since TNFR2 half-life is 
longer (4 hours) than TNFα half-life (~ 6 min), 
it exhibits superior sensitivity and reliability 
when measuring in frozen plasma. Therefore, 
TNFR2 is used as an effective surrogate marker 
of TNFα activity.
Type 2 diabetes (T2D) is a metabolic disor-
der characterized by hyperglycemia, which re-
sults from progressive insulin secretory defect 
on the background of insulin resistance [7]. For 
30 years now, periodontitis has been acknowl-
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edged as the sixth chronic complication of diabetes [8]. 
There is increasing evidence that the relationship between 
T2D and periodontitis is bidirectional [9]. Roles of TNFα 
in pancreatic β-cell destruction and insulin resistance have 
been established [10].
OBJECTIVE
This study was aimed at detecting TNFR2 serum concen-
tration and correlating it with periodontal destruction in 
type 2 diabetics and nondiabetics.
METHODS
Study population
The study was conducted as a cross-sectional study, ap-
proved by the Ethical Committee of the Faculty of Dental 
Medicine, University of Belgrade (decision No. 36/9 of 20th 
of February 2013) between March 2013 and January 2014. 
A total of 85 subjects (41 men and 44 women, 28–68 years 
of age) were divided into three groups: healthy control (HC) 
group consisted of 24 healthy volunteers without clinical 
signs of periodontitis and free of systematic diseases; perio-
dontitis group (PD) consisted of 27 patients with diagnosed 
chronic periodontitis (CP) and free of systematic diseases 
(periodontitis patients were referred to Department of Peri-
odontology and Oral Medicine, Faculty of Dental Medi-
cine, University of Belgrade); 34 patients, hospitalized at the 
Clinic for Endocrinology, Diabetes and Metabolic Diseases, 
Clinical Center of Serbia, with diagnosed T2D and CP com-
prised the T2D group. All the subjects who participated in 
the study signed an informed consent.
Inclusion and exclusion criteria
The subjects included in study had more than 14 teeth and 
body mass index (BMI) of 18–30 kg/m2. The exclusion 
criteria were as follows: pregnancy/lactation, presence of a 
systemic disease except T2D and its chronic complications, 
injury in the previous six months, systemic antibiotic/im-
munomodulatory therapy in the previous three months, 
therapy of periodontitis during 18 months prior to the 
study, everyday usage of oral antiseptics.
Anamnesis of the patients and clinical examination
Data regarding smoking history, mental stress, physical 
activity and health status were obtained through clinical 
chartings and interviews. Patients were classified accord-
ing to their smoking status as “nonsmoker” and “smoker”. 
Smokers were further classified as “former smoker” (with 
subgroups consisted of subjects who ceased smoking more 
or less than five years ago, respectively) or “current smoker” 
(with subgroups smoking more or less than 10 cigarettes 
per day, respectively). Pack-years (PPY) were calculated by 
multiplying duration of smoking in years and the number 
of cigarettes smoked per day, and then dividing by 20. Pa-
tient histories included information about the subjects’ 
everyday mental stress in terms of intensity and frequency. 
The final score was calculated as the sum of the mentioned 
measurements, and categorized as low/medium/high stress 
[11]. Information about the intensity (low, moderate, hard), 
frequency (never, less/more than 2 times/week) and type 
(aerobic/anaerobic) of physical exercise was also recorded.
T2D and chronic periodontitis diagnosis
T2D was diagnosed by measuring glycaemia using oral 
glucose tolerance test (OGTT), as well as glycated hemo-
globin (HbA1c) values [7]. Nondiabetics exhibited normal 
parameters on OGTT and HbA1c < 6.5%. The blood sugar 
regulation was classified as satisfactory (HbA1c ≥ 7.5%) 
and poor control (HbA1c < 7.5%).
A full-mouth clinical examination performed at six sites 
per tooth was done for each tooth in order to asses the fol-
lowing periodontal parameters: Silness–Löe plaque index 
(PI), dichotomous bleeding on probing (BOP), probing 
pocket depth (PPD) and clinical attachment loss (CAL). 
All examinations were performed by two calibrated doc-
tors – one collected the measurements using Williams 
probe (Hu-Friedy Mfg. Co., LLC, Chicago, IL, USA) and 
the other recorded the results. Periodontitis was diagnosed 
if the subject exhibited CAL > 1 mm and PPD > 3 mm at 
least at three sites in two different quadrants. According 
to CAL, periodontitis patients were classified into the fol-
lowing three subgroups: patients with mild CP (CAL = 1–2 
mm); moderate CP (CAL = 3–4 mm), and severe CP (CAL 
≥ 5 mm). Periodontitis was defined as localized/general-
ized depending on the number of affected sites (more/less 
than 30%, respectively) [12]. The inflammatory impact 
from periodontium on general health was calculated using 
periodontal epithelial surface area (PESA) and periodontal 
inflamed surface area (PISA) [13]. Calculations were done 
by using Excel (Microsoft Corporation, Redmond, WA, 
USA) spreadsheets available at http://www.parsprototo.
info/ using PPD, CAL, recession for PESA, and addition-
ally BOP for PISA on each tooth. Results were presented 
in mm2. Patients without clinical signs of periodontitis had 
PPD < 3 mm and CAL = 0 mm.
Blood sampling and measurements
Venous blood was collected from cubital vein day after 
periodontal examination, following fasting, in the resting 
state in the morning, between 7 and 9 a.m., to minimize 
diurnal variations. Total leukocyte count, plasma concen-
trations of cholesterol, high and low density lipoproteins, 
triglycerides, fibrinogen, HbA1c, sedimentation rate, and 
fasting plasma glucose (FPG) levels were measured. Sera 
obtained from blood samples for TNFR2 analysis were im-
mediately frozen at -72°C and stored until use.
The TNFR2 level was measured by the enzyme-linked 
immunosorbent assay (ELISA) (eBioscience, Human 
TNFR2 Platinum ELISA, San Diego, CA, USA) as described 






The sample size calculation using literature based data for 
TNFR2 level as a reference variable showed that sample 
size with 25 patients in each group would provide 80% of 
power and significance level (α) of 5%.
The statistical analysis package SPSS 18.0 (SPSS Sta-
tistics for Windows, SPSS, Inc., Chicago, IL, USA) was 
used. Categorical variables were compared using the 
chi-square test (χ2). Numeric data were tested for nor-
mal distribution using the Kolmogorov–Smirnov test. 
For normally distributed data, Student’s t-test / One Way 
ANOVA was used. Non-parametric data were analyzed 
using the Kruskal–Wallis / Mann–Whitney U-test. Spear-
man’s/Pearson’s correlation coefficients were obtained in 
order to assess the relationship between TNFR2 concen-
trations and clinical parameters. Linear regression model 
was used to determine the predictors of TNFR2. Reliability 
was tested by Cohen’s kappa test. The Cohen’s kappa score 
was determined for each periodontal index in order to test 
intraobserver agreement. Participants with missing data 
were not included in the study. All reported p-values were 
two-sided. Differences were considered significant when 
p-value was <0.05.
RESULTS
Demographic data and clinical measurements
A total of 170 patients were examined. After anamnesis, 
and clinical and biochemical examinations, 97 were re-
cruited for the study. According to ELISA plate size, we 
analyzed only 88 samples. Considering that absorbance of 
three samples were not detectable, results were obtained 
for 85 patients. 
Demographic data and clinical measurements are pre-
sented in Table 1. Groups are matched by age and gender. 
Although the BMIs were 18.0–30.0 kg/m2, BMI differed 
between T2D and two other groups. HbA1c and FPG 
levels were higher in T2D than in HC and PD groups. 
The groups were similar by smoking status (χ2, p > 0.05). 
Regarding T2D management, 19 subjects used oral an-
tidiabetics, 10 were on insulin therapy and five were on 
combined insulin therapy.
There was a significant difference in the clinical peri-
odontal parameters between the groups (Table 2). Inter-
group analysis revealed differences for PI and CAL be-
tween all groups (Маnn–Whitney U-test, p = 0.000). BOP 
and PPD did not differ between PD and T2D groups (Bon-
ferroni > 0.05). Number of present teeth was higher in 
HC than in other groups (Bonferroni, p < 0.05). PESA 
and PISA were similar between T2D and PD groups. The 
kappa score for clinical parameters were 0.5–0.8, repre-
senting very good agreement.
TNFR2 concentrations
There was no difference in TNFR2 concentrations between 
the groups. Average concentration in HC, PD and T2D 
groups were respectively 4.8 ± 4.680, 4.9 ± 7.366, and 
5.2 ± 9.719, expressed in ng/ml. TNFR2 serum concentration 
of diabetics with and without complications were 6.22 ± 11.94 
and 4.22 ± 5.54 ng/ml, respectively.
Relationship between TNFR2 concentrations and 
periodontal clinical parameters
A significant correlation was observed between CAL and 
TNFR2 concentrations in PD and CAL, PESA, PISA, and 
TNFR2 in T2D groups (Table 3). Difference was not ob-
served between the concentration of TNFR2 and extent of 
periodontitis neither in T2D (p = 0.674, Mann–Whitney) 
nor in PD group (p = 0.487, Mann–Whitney).
Relationship between TNFR2 concentrations and 
biochemical parameters
Pearson’s correlation coefficient between TNFR2 concen-
trations and BMI in all patients (r = 0.025, p = 0,822) and 
each group were positive but nonsignificant (HC group: 
r = 0.248, p = 0.248; PD group: r = 0.054, p = 0.79; T2D 
group: r = 0.067, p = 0.708).
According to the smoking status, there was significant 
difference between TNFR2 concentrations (smokers: 5.6 
± 3.738 ng/ml; non-smokers: 4.4 ± 8.713 ng/ml; p = 0.02, 




Healthy control Chronic periodontitis Type 2 diabetes
Age 42.0 ± 3.709 44.9 ± 12.494 46.1 ± 7.606 0.078a




















Results are presented as mean ± standard deviation (SD). Results for discrete measures are presented as percentage (%).
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Kruskal–Wallis) in PD group. In this group, a correlation 
between PPY and TNFR2 concentrations were observed 
(r = 0.424, p = 0.028, Spearman’s correlation coefficient).
The concentrations of TNFR2 were neither influenced by 
the levels of self-reported stress (Kruskal–Wallis, p = 0.459) 
nor by parameters of physical exercise (Kruskal–Wallis, p 
> 0.05). Spearman’s correlation revealed a weak positive 
but nonsignificant correlation between TNFR2 and HbA1c 
concentrations (r = 0.015, p = 0.935), and duration of T2D 
(r = 0.05, p = 0.781).
 In linear regression analysis, none of the parameters 
(hematological and biochemical data, physical exercise, 
mental stress, smoking status, clinical periodontal pa-
rameters, duration of diabetes) were assessed as univari-
ate predictors.
DISCUSSION
This study investigated serum concentrations of TNFR2 
in T2D patients with periodontitis, and compared them 
with serum TNFR2 levels in nondiabetics with periodon-
titis and subjects with clinically healthy periodontium. 
T2D and periodontitis both are chronic inflammatory 
disorders which share certain pathogenetic mechanisms, 
have common inflammatory mediators, although they 
are of different etiological origin. Advanced periodontitis 
is considered to be a source of inflammatory mediators. 
On the other hand, low-grade inflammation precedes dia-
betes. The role of inflammatory mediators derived from 
chronically inflamed periodontium and its influence on 
diabetes onset is yet to be determined [14]. Most published 
studies investigating inflammatory mediators originated 
from periodontium have been done in systemically healthy 
subjects. In contrast, studies with diabetic patients did not 
take into consideration influence of periodontal inflam-
mation, which surely should not be neglected. We did not 
find differences in TNFR2 serum concentration between 
the groups. Local production of both receptors is elevated 
in periodontal pockets > 3 mm, but their levels progres-
sively diverged as the PPD increased, with the TNFR2 level 
being comparatively lower than TNFR1 [5]. Although local 
TNFR2 concentration was negatively correlated with PPD 
and is considered to be protective for periodontal tissues, 
serum TNFR2 concentrations were not increased after 
treatment [9]. It is possible that local periodontal produc-
tion of receptors is not sufficient for a detectable change of 
serum concentrations. The results of studies dealing with 
local periodontal production of TNF family are conflicting: 
although it is almost accepted that diabetes elevates local 
cytokine production [15], one study showed lower amount 
of TNFα in gingival crevicular fluid (GCF) in T2D + PD 
than in PD patients [16]. Elevated concentrations of both 
receptors are detected in diabetics with complications [17]. 
In our study we found slightly increased TNFR2 levels in 
patients with chronic complications of diabetes. 
This study tried to determine systemic inflammatory/
infectious burden originating from periodontium using 
PISA and PESA calculation. There is a limited number of 
studies investigating PISA–T2D relationship, but all are 
related to HbA1c level [18]. As mentioned in the Methods 
section, PESA and PISA are calculated using PPD, CAL, 
gingival recession, and BOP. As BOP correlates to PI, we 
took into consideration all clinical periodontal parameters. 
Statistical correlation was found between CAL and TNFR2 
in T2D and PD groups. Significant correlations between 
PISA/PESA and TNFR2 were observed in diabetics. In 
PD group, CAL–TNFR2 correlation was negative. This 
negative correlation is in agreement with the study that 
Table 3. Pearson’s correlation coefficient (r) between periodontal 
parameters and TNFR2 serum concentrations in periodontitis and 
type 2 diabetes groups












PPD – probing pocket depth; CAL – clinical attachment level; PESA – peri-
odontal epithelial surface area; PISA – periodontal infl amed surface area




Healthy control Periodontitis Type 2 Diabetes
PI (Silness–Löe) 0.8 ± 0.499 1.5 ± 0.725 2.1 ± 0.815 0.000a
BOP (%) 34.8 ± 17.307 59.8 ± 23.646 63.0 ± 29.409 0.000a
PPD (mm) 1.9 ± 0.434 2.7 ± 0.544 2.6 ± 0.116 0.048a
CAL (mm) 0.0 2.4 ± 1.909 4.1 ± 1.944 0.001b







Number of present teeth 27.3 ± 1.681 21.6 ± 3.974 19.6 ± 3.544 0.000a
PESA (mm2) N/A 1046.2 ± 292.66 976.9 ± 271.84 0.343d
PISA (mm2) N/A 694.7 ± 359.75 720.0 ± 421.79 0.804d
Results are presented as mean ± SD. PPD and CAL values presents average of all sites, including aff ected and unaff ected sites.
PI – plaque index; BOP – bleeding on probing; PPD – probing pocket depth; CAL – clinical attachment level; PESA – periodontal epithelial surface area; PISA – 
periodontal infl amed surface area
a One-way ANOVA
b Kruskal–Wallis test






found negative correlation of  local TNFR2/TNFR1 ratio 
with PPD, and increasing of this ratio after scaling and 
root planning [9]. It seems that reduction of inflamma-
tion leads to increase of local TNFR2 concentration. The 
same study also measured receptor serum level before and 
after the treatment and did not show any differences in 
serum TNFR2 level due to its long-term stable concen-
tration. Also, measuring the serum TNFα and receptors 
concentration, Ikezawa et al. [5] found decreased ratio of 
serum TNFR2/TNFR1 at periodontitis vs. healthy subjects 
(p = 0.051). This finding also supports a pro tective role of 
TNFR2 in periodontal tissues. These findings are in cor-
relation with our results supporting the role of TNFR2 in 
periodontitis. The TNFR2 is directly involved in TNFα sig-
naling pathways and is considered as prosurvival receptor, 
which suppresses basal osteoclastogenesis [6, 19]. While 
TNFα and TNFR1 are overexpressed in gingival tissues 
at periodontitis, TNFR2 is sporadically found in infiltrat-
ing monocyte/macrophage cells and gingival fibroblasts, 
which may be explained as unsuccessful attempt of gingi-
val tissue to neutralize detrimental effects of TNFα [20]. 
This in agreement with our results, which support the 
negative correlation between TNFR2 concentration and 
CAL in nondiabetic periodontitis patients.
In T2D group, we found significant and positive cor-
relation between CAL/PESA/PISA and serum TNFR2 
concentration. Our results lead to the assumption which 
is in agreement with other studies – that diabetes through 
extended TNFα/receptors expression changes the inflam-
matory reaction and thereby response to periodontal path-
ogens [16, 21]. The aforementioned changes in inflam-
matory response may lead to exaggerated vulnerability to 
systematic consequences of local infection. TNFα is im-
plicated in insulin resistance mechanism [10], and serum 
TNFR2 levels and/or adiponectin concentration are good 
prediction markers of T2D onset [22]. Increased TNFR2/
TNFR1 ratio is associated with insulin resistance [23]. Al-
most all studies which explored TNFα level in diabetics 
did not take into consideration periodontal inflammation. 
Engebretson et al. [14] considered the periodontal status 
in T2D patients and demonstrated that severity of chronic 
periodontitis was associated with increased TNFα level in 
T2D patients and found a positive correlation between the 
TNFα serum concentration and CAL.
According to some studies, BMI could influence TNFR2 
[24]. We did not find correlation between BMI and TNFR2 
in total of 85 patients and separately for each group which 
is in accordance with most of the studies correlating BMI 
with TNFα and/or its receptors [10, 14, 17]. 
TNFα and its receptors serum level could be influ-
enced by emotional stress [25], regular exercise [26], and 
smoking [27]. According to the results of our study, self-
reported evaluation of the aforementioned parameters 
could not be considered to be an independent predictor 
of TNFR2 concentration. To the best of our knowledge, this 
is the first study that took into consideration these factors 
when examining the influence of periodontitis and T2D 
on cytokine level.
We observed a higher TNFR2 concentration in smokers 
in the PD group. This group showed a significant correla-
tion between PPY and TNFR2 concentration. Although 
a relationship between cigarette consumption and TNFα 
release from macrophages has been reported [27], results 
about correlation of smoking and TNFR2 serum concen-
tration are still inconsistent [9]. 
TNFR2 reflects chronic activation of TNFα and has 
inducible but relatively stable concentration and may act 
both as an inhibitor and depot of TNFα [9]. It transduces 
the most prosurvival signals, buffers TNFα [21], and has 
certain roles in pathogenesis of peridontitis[19, 28] and 
diabetes [22, 23]. In our study we could not detect any 
predictors of TNFR2 concentration using regression sta-
tistical models.
CONCLUSION
TNFR2 showed negative correlation with periodontal de-
struction in nondiabetics, but its dysregulated production 
and function in T2D may affect this correlation and its 
potential protective effect. Measuring circulating levels 
of proinflammatory cytokines is more accurate at animal 
models, because of the strong influence of environmental 
factors on expression of these cytokines in humans.  Larger 
and more controlled studies, which take into consideration 
genetic background, are needed to confirm these findings. 
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Увод Улога фактора некрозе тумора-алфа (TNFα) доказана 
је у патогенези хроничне пародонтопатије (ХП) и дијабетеса 
мелитуса типа 2 (ДМ тип 2). С обзиром на то да је полужи-
вот TNFα веома кратак, рецептор 2 фактора некрозе тумора 
(TNFR2) користи се као маркер активности TNFα.
Циљ рада Циљ овог рада је одређивање концентрације 
TNFR2 у серуму и корелирање са параметрима деструкције 
пародонцијума код здравих и испитаника са дијагностико-
ваним ДМ тип 2.
Методе рада У студију је укључено 85 пацијената подеље-
них у три групе: ДМ тип 2 + ХП (ДМ група, n = 34), здрави 
испитаници + ХП (ПД група, n = 27) и здраве контроле (ЗК 
група, n = 24). Дијагноза ДМ тип 2 постављена је на основу 
критеријума СЗО (2013), док је дијагноза ХП постављена на 
основу критеријума Интернационалне радионице за класи-
фикацију стања и обољења пародонцијумa (1999). Концен-
трација TNFR2 мерена је ELISA методом.
Резултати Концентрација серумског TNFR2 није се разли-
ковала међу групама (Краскал–Волис, p = 0,482). Постоји 
значајна корелација (Пирсон) између нивоа припојнoг епи-
тела (НПЕ) и концентрације TNFR2 у ПД групи (rp = -0,460, p 
= 0,016). У ДМ тип 2 групи, статистички значајна корелација 
уочена је између концентрације TNFR2 и НПЕ (rp = 0,363, p = 
0,005), као и параметара утицаја инфламације из пародон-
цијума на системско здравље – PISA (rp = 0,345, p = 0,046) и 
PESA (rp = 0,578, p = 0,000).
Закључак Код пацијената са дијабетесом веће концентра-
ције TNFR2 одговарају већим вредностима НПЕ, PESA и PISA. 
Насупрот томе, код системски здравих испитаника са ХП 
веће вредности НПЕ су повезане са мањим концентрација-
ма TNFR2, што би могло говорити о потенцијалној заштитној 
улози овог цитокина на деструкцију пародонцијума. Резул-
тати говоре да дијабетес може утицати на секрецију TNFR2 
из пародонцијума.
Кључне речи: хронична пародонтопатија; TNFR2; TNFα; дија-
бетес мелитус тип 2
Корелација између концентрације рецептора 2 фактора некрозе тумора у 
серуму и деструкције пародонцијума код болесника са дијабетес мелитусом 
тип 2: студија пресека 
Сања Матић-Петровић1, Ана Пуцар1, Александра Јотић2,3, Биљана Миличић3,4, Јелена Арамбашић-Јовановић5, 
Мелита Видаковић5, Војислав Лековић1
1Универзитет у Београду, Стоматолошки факултет, Клиника за оралну медицину и пародонтологију, Београд, Србија;
2Универзитет у Београду, Медицински факултет, Београд, Србија;
3Клинички центар Србије, Клиника за ендокринологију, дијабетес и поремећаје метаболизма, Београд, Србија;
4Универзитет у Београду, Стоматолошки факултет, Катедра за медицинску информатику и статистику, Београд, Србија;
5Институт за биолошка истраживања, Одељење за молекуларну биологију, Београд, Србија
Примљен • Received: 28/04/2015 Ревизија • Revision: 14/07/15  Прихваћен • Accepted: 06/11/2015
